New immune cells targeting advanced ovarian cancer that hasn't responded to standard treatment

Plain-English translation of NCT07617753 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated June 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This trial is testing a new type of treatment called CAR-NK cells, which are immune cells that have been engineered in a laboratory to recognize and attack ovarian cancer. The treatment is personalized—doctors will first test your tumor to see which cancer-fighting targets it has, then give you CAR-NK cells designed specifically to target those markers. The medication is delivered directly into your abdomen where the cancer is, giving it the best chance to work.

Ovarian cancer that comes back or stops responding to standard chemotherapy is very difficult to treat, and patients need new options. This treatment is designed to harness your own immune system in a more targeted way to fight cancer cells that other treatments can no longer control.

Do you qualify?

You likely qualify if…

you have been diagnosed with high-grade serous ovarian, fallopian tube, or primary peritoneal cancer
your cancer has come back or stopped responding to at least two previous chemotherapy treatments
your tumor has measurable disease that can be seen on imaging scans
your tumor's cells express at least two of three specific cancer markers (tested from a biopsy or archived tissue)
you are in good enough health to receive this treatment (good organ function, ability to walk and care for yourself most of the day)

You likely don't qualify if…

you have received any prior gene-modified cell therapy (like CAR-T or CAR-NK) in the past 6 months
you have active cancer that has spread to your brain or spinal fluid requiring treatment
you have an active, uncontrolled infection, including active tuberculosis or uncontrolled viral infections
you have significant heart disease, recent heart attack, or uncontrolled irregular heartbeats
you are pregnant, breastfeeding, or unwilling to use effective birth control for 12 months after treatment

What participation looks like

First, doctors will take a small sample of your tumor (either from an old biopsy or a new one) to test which cancer markers it has and determine which version of the engineered cells you should receive. You will then receive chemotherapy to prepare your body, followed by an infusion of the engineered immune cells delivered directly into your abdomen through a small implanted port. You'll be monitored closely for side effects and response to treatment, with regular check-ups, blood tests, and imaging scans for at least 12 months, and follow-up visits for up to 24 months.

AI-generated summary from trial data · Jun 6, 2026 · Not medical advice

Trial locations(1 site)

China

Peking University Shenzhen Hospital, Shenzhen, Guangdong